logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

NIO, a company deeply involved in the development of Singapore's new electric charging standards, has been launched.

date
10/06/2026
"WECHAT" official account of NIO, in recent times, the new Singapore electric vehicle charging and swapping standard "Singapore Standard SS 722" developed and deeply involved by NIO has been officially launched.
Latest
1 m ago
Relaxed Health (02661.HK) signed a strategic cooperation memorandum with Basel Medical to achieve mutual development of technology output and technology iteration.
1 m ago
Shiyao Group (01093.HK): Anituximab monoclonal antibody (KN026) combined with injection of albumin-bound doxorubicin (HB1801) in the first-line treatment of HER2-positive advanced breast cancer reached the primary endpoint in Phase III study.
3 m ago
UK Prime Minister Stammer: The violence and arson attacks in Belfast are completely senseless.
3 m ago
Relaxed and healthy: Signed a three-year strategic cooperation memorandum with Basel Medical Group Limited.
3 m ago
Shiyao Group: The Phase III study of the combination of Annuity Monoclonal Antibody and HB1801 for the first-line treatment of HER2-positive advanced breast cancer has reached the primary endpoint.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.